Full-Time
BlueRock Therapeutics
201-500 employees
Develops advanced cellular therapies for diseases
Compensation Overview
$325k - $350k/yr
Expert
New York, NY, USA
- PhD in Biomedical Sciences, Molecular Biology, Neuroscience, Stem Cell Biology, or M.D. with 12+ years of relevant experience
- Experience leading a program
- Proven track record in pharmaceutical/biotechnology with scientific excellence
- Experience with IND-enabling studies and filings
- Deep knowledge of developmental neuroscience and pluripotent stem cell biology
- Expertise in neurological disease, neuroinflammation, regenerative medicine, assay development, biomarkers, CMC, and regulatory
- Strong written, analytical, and verbal communication skills
- Leadership experience in a collaborative, high-growth environment
- Innovative, results-oriented, and critical thinking skills
- Drive the strategy and execution of BlueRock’s cell therapy pipeline from concept to IND filing
- Lead scientific direction, hiring, and budgeting for your team
- Provide strategic input into Neuroscience cell programs
- Evaluate cell:disease pairings and integrate them into a research plan
- Mentor direct reports and promote BlueRock’s values of urgency, integrity, community, and courage
- Build and maintain relationships with leaders in the organization
- Establish efficient processes, standards, and SOPs
- Collaborate with Development and Technical Operations
BlueRock Therapeutics develops cellular therapies using a unique gene platform to create medicines for neurology, cardiology, and immunology. Their technology allows for the genetic engineering of cells to treat complex diseases like neurodegenerative disorders and heart failure. Unlike competitors, BlueRock focuses on strategic partnerships and research to advance their therapies, generating revenue through collaborations and licensing agreements. The company's goal is to address challenging medical conditions with a new generation of effective cellular treatments.
Company Size
201-500
Company Stage
Acquired
Total Funding
$1.2B
Headquarters
Cambridge, Massachusetts
Founded
2016
Simplify's Take
What believers are saying
- FDA RMAT designation for bemdaneprocel accelerates market entry for Parkinson's therapy.
- Successful Phase I trial of bemdaneprocel boosts investor confidence and funding potential.
- Collaboration with bit.bio enhances discovery and development of new cell therapies.
What critics are saying
- Competition from established firms like Johnson & Johnson may overshadow BlueRock's innovations.
- Reliance on strategic partnerships poses risks if partners shift focus or resources.
- Regulatory hurdles could delay product launches, impacting revenue and market position.
What makes BlueRock Therapeutics unique
- BlueRock uses iPSC technology to create novel cellular therapies for complex diseases.
- Their strategic partnerships enhance R&D capabilities and expand therapeutic applications.
- Focus on neurology, cardiology, and immunology addresses challenging medical conditions.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 2%OpCT-001 is the first iPSC therapy candidate licensed from the strategic research and development alliance that FUJIFILM Cellular Dynamics, Opsis Therapeutics, and BlueRock Therapeutics entered in 2021 to discover and develop off-the-shelf iPSC-derived cell therapies for ocular diseases.
Since May 2021, BlueRock Therapeutics, Fujifilm Cellular Dynamics, and Opsis Therapeutics have had an R&D alliance to develop allogeneic iPSC-derived cell therapies for ocular diseases.
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to bemdaneprocel, a cell therapy BlueRock Therapeutics, a subsidiary of Bayer, is developing to treat Parkinson's disease.
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year.At one-year, exploratory clinical endpoints improved overall, with participants in the high dose cohort showing greater improvement.One year assessment of all participants demonstrated feasibility of transplantation, cell survival, and engraftment.Planning is underway for a Phase II study that is expected to begin enrolling participants in H1 (first half) 2024.BERLIN and CAMBRIDGE, Mass., Aug. 28, 2023 /PRNewswire/ -- Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today details of the positive data from the Phase I clinical trial for bemdaneprocel (BRT-DA01), a stem cell derived investigational therapy for treating Parkinson's disease. The data were presented at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark.The study met the primary objective of demonstrating safety and tolerability in all 12 participants in the study's low and high dose cohorts, with no serious adverse events (SAEs) reported related to bemdaneprocel through one year. There were two SAEs reported that were unrelated to bemdaneprocel, one seizure attributed to the surgical procedure and one COVID case. Both resolved without sequelae. In addition, 18F-DOPA PET imaging scans demonstrated evidence of cell survival and engraftment in both low and high dose cohorts
BlueRock and bit.bio link to develop regulatory T cell-based therapies.